EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Targeting endothelin signaling in podocyte injury and diabetic nephropathy-diabetic kidney disease

Maulana Antiyan Empitu iD, Pranindya Rinastiti iD, Ika Nindya Kadariswantiningsih iD

Journal of Nephrology · 2024

DOI: 10.1007/s40620-024-02072-w ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Nephrology, 2024. Verfasst von Maulana Antiyan Empitu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Airlangga University, Surabaya, Indonesia. Hauptthemen laut MEDLINE: Diabetic Nephropathies, Podocytes, Endothelin Receptor Antagonists, Endothelin-1. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 69 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite advances in diabetes management, there is an urgent need for novel therapeutic strategies since the current treatments remain insufficient in halting the progression of diabetic nephropathy-diabetic kidney disease (DN-DKD). This review is mainly addressed on the pivotal role of endothelin-1 in the pathophysiology of DN, with a specific focus on its effects on podocytes and the glomerular filtration barrier. Endothelin-1 promotes mesangial cell proliferation, sclerosis, and direct podocyte injury via the activation of endothelin type A and B receptors, that drive the progression of glomerulosclerosis in DN-DKD. Endothelin receptor antagonists, including drugs like atrasentan and sparsentan, have demonstrated nephroprotective effects in experimental models by reducing proteinuria and podocyte injury. The therapeutic potential to slow the progression of DN to end-stage kidney disease (ESKD) of these endothelin receptor antagonists in clinical practice is currently under evaluation. However, fluid retention and increased risk of heart failure associated with endothelin receptor antagonists need careful consideration. This review aims to provide an in-depth analysis of the pathophysiological role of endothelin and the emerging therapeutic implications of targeting this pathway in DN-DKD and discusses efficacy, safety, and the possibility of combining the new generation of endothelin receptor antagonists with the standard treatment of CKD and DN-DKD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetic NephropathiesPodocytesEndothelin Receptor AntagonistsEndothelin-1EndothelinsHumansSignal TransductionAnimalsReceptor, Endothelin A

Stichwörter der Autor:innen

Diabetic nephropathyEndothelin receptor antagonistEndothelin-1MedicinePodocyte

Substanzen

Endothelin Receptor AntagonistsEndothelin-1EndothelinsReceptor, Endothelin A

Autor:innen und Institutionen

  • Faculty of Medicine, Airlangga University, Surabaya, Indonesia.
  • Faculty of Health, Medicine and Natural Sciences (FIKKIA), Airlangga University, Banyuwangi, Indonesia.
  • Laboratory of Clinical Pharmaceutical Science, Kobe Pharmaceutical University, Kobe, Japan.
  • Department of Clinical Pathology, Faculty of Medicine, Public Health, and Nursing, Gadjah Mada University, Yogyakarta, Indonesia.
  • Faculty of Medicine, Airlangga University, Surabaya, Indonesia. ika.nindya@fk.unair.ac.id.

ORCID-Profile: Maulana Antiyan Empitu, Pranindya Rinastiti, Ika Nindya Kadariswantiningsih

Zitieren

APA

Empitu, M. A., Rinastiti, P., & Kadariswantiningsih, I. N. (2024). Targeting endothelin signaling in podocyte injury and diabetic nephropathy-diabetic kidney disease. Journal of Nephrology. https://doi.org/10.1007/s40620-024-02072-w

Vancouver

Empitu MA, Rinastiti P, Kadariswantiningsih IN. Targeting endothelin signaling in podocyte injury and diabetic nephropathy-diabetic kidney disease. Journal of Nephrology. 2024. doi:10.1007/s40620-024-02072-w

BibTeX
@article{Empitu2024,
  author = {Empitu, Maulana Antiyan and Rinastiti, Pranindya and Kadariswantiningsih, Ika Nindya},
  title = {Targeting endothelin signaling in podocyte injury and diabetic nephropathy-diabetic kidney disease},
  journal = {Journal of Nephrology},
  year = {2024},
  doi = {10.1007/s40620-024-02072-w}
}
Kostenlos starten →